Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2018

View Archived Issues

Messenger RNA can treat porphyria

Neurons can switch transmitter allegiance in vivo

Astellas Cathespin S inhibitors prolong graft survival in a mouse cardiac transplant model

Targeted cancer therapy leads to twist of cell fate

Brigham Young University patents therapeutic bacteriophages

[18F]FC-303, an 18F-labeled PSMA radiotracer for PET imaging of prostate cancer

Shanghai De Novo Pharmatech identifies Wee1-like protein kinase inhibitors

Hefei Amvite Pharmaceutical and collaborators identify platelet adhesion inhibitors

SQZ Biotech expands cellular therapy partnership with Roche

Phase I/II study of KB-103 meets all primary efficacy and safety endpoints at interim data analysis

Soligenix receives recommendation to continue phase III FLASH study of SGX-301

TherapyX and Intravacc partner to develop Ngoxim prophylactic vaccine against gonorrhea

Cellect reports promising data from phase I/II study of ApoGraft technology

Dupixent reduces nasal polyp size and nasal congestion severity in phase III trials

[18F]HTK-01174 shows promise for PET imaging of prostate cancer

BARDA funding to support pediatric studies of Stratagraft for thermal burns

NIH grant supports Allele's development of nanoantibodies to treat sepsis

Praliciguat shows promise in phase IIa study in patients with type 2 diabetes and hypertension

Studies evaluate autologous tolerogenic dendritic cells in multiple sclerosis patients

ADAMTS7 as indicator of early left ventricular diastolic and systolic dysfunction in type 2 diabetes

VenatoRx presents pharmacokinetic and safety data for VNRX-5133

Inherited polymorphisms contribute to increased risk for Waldenstrom macroglobulinemia

Liposome adjuvant increases the immunogenicity of malaria vaccines

OncoSec initiates KEYNOTE-890 phase II study of Tavo plus Keytruda for TNBC

Athenex reports initial pilot results for T-cell receptor affinity enhancing specific T-cell therapy

Restorbio reports additional phase IIb data on RTB-101

FDA clears IND for phase I trial of CK-0801 in treatment-resistant Guillain-Barre syndrome

Axsome to develop AXS-12 for narcolepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...